Virtu Financial LLC Invests $44,000 in Protalix BioTherapeutics, Inc. (NYSE:PLX)

Virtu Financial LLC bought a new stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 43,388 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 0.06% of Protalix BioTherapeutics as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Protalix BioTherapeutics during the third quarter valued at about $36,000. GSA Capital Partners LLP raised its stake in Protalix BioTherapeutics by 8.5% during the 3rd quarter. GSA Capital Partners LLP now owns 435,213 shares of the company’s stock worth $444,000 after buying an additional 33,969 shares during the period. Cubist Systematic Strategies LLC bought a new position in Protalix BioTherapeutics in the second quarter worth approximately $37,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Protalix BioTherapeutics in the second quarter valued at approximately $80,000. Finally, AQR Capital Management LLC bought a new stake in shares of Protalix BioTherapeutics during the second quarter valued at approximately $67,000. 16.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, StockNews.com upgraded Protalix BioTherapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 12th.

Protalix BioTherapeutics Price Performance

Shares of NYSE PLX opened at $1.76 on Friday. The company has a 50-day moving average price of $1.44 and a 200-day moving average price of $1.20. The stock has a market capitalization of $129.60 million, a P/E ratio of -13.54 and a beta of 0.74. Protalix BioTherapeutics, Inc. has a 1 year low of $0.82 and a 1 year high of $1.90.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.